Global /United States /Healthcare /Biotechnology /SHRX

Sharp Therapeutics Corp.

SHRX

• TSXV: SHRX • Delayed

2.10CAD 0%

1.51 USD

As of 13 June 2026, Sharp Therapeutics Corp. has a market cap of $45.18M USD, ranking #31306 globally and #4531 in the United States. It ranks #2829 in the Healthcare sector, and #547 in the Biotechnology industry.

Global Rank

31306

Country Rank

4531

Sector Rank

2829

Industry Rank

547

Key Stats

Market Cap

$45.18MUSD

63.16M CAD

Enterprise Value

$45.59MUSD

63.61M CAD

EBITDA (TTM)

-$5.4MUSD

-7.54M CAD

Net Income (TTM)

-$6.06MUSD

-8.47M CAD

PB Ratio

-260.8

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Scott Sneddon open_in_new

Website

sharptx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-2.3%	-6.7%	-12%	-38%	-16%	163%	91%	91%

News

Markets

Exchange	Ticker	Price	Quotes
TSX Venture Exchange (TSXV) MIC: XTSX PRIMARY	SHRX Sharp Therapeutics Corp ISIN: CA8200092077 TV: TradingView: TSXV: SHRX SA: Stock Analysis: TSXV: SHRX YF: Yahoo Finance: SHRX.V GF: Google Finance: CVE: SHRX BA: Barron's: SHRX MS: Morningstar: XTSX: SHRX	2.10 CAD	TV: TradingView: TSXV: SHRX SA: Stock Analysis: TSXV: SHRX YF: Yahoo Finance: SHRX.V GF: Google Finance: CVE: SHRX BA: Barron's: SHRX MS: Morningstar: XTSX: SHRX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sharp Therapeutics Corp.

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 404K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 354K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 61K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 58K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 55K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 40K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 106K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 99K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 94K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 94K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 62K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 57K%	-	Germany

chevron_leftBack